Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.
ProPhase Labs saw a decrease in earnings per share from 0.4 in Q2 to $0.06 now. Most recently, Aptevo Therapeutics reported earnings per share at $-1.5, whereas in Q2 earnings per share sat at $-1.82. Global Cord Blood saw a decrease in earnings per share from 0.17 in Q3 to $0.14 now. Jasper Therapeutics saw a decrease in earnings per share from -0.29 in Q2 to $-0.32 now. Fulgent Genetics's earnings per share for Q3 sits at $0.32, whereas in Q2, they were at 0.78.
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.